Introduction
In late March to early April of 2009, a novel influenza virus of swine origin emerged in humans in Mexico and the USA and rapidly spread worldwide, prompting the WHO to declare an influenza pandemic [1] [2] [3] . This is the first influenza pandemic since the A(H3N2) Hong Kong pandemic of 1968. The pandemic A(H1N1) 2009 virus [A(H1N1)pdm09] was initially found to be susceptible to neuraminidase inhibitors, oseltamivir and zanamivir, but resistant to amantadine [4] . In the course of the pandemic in the 2009-2010 period, sporadic cases of oseltamivir-resistant strains were detected around the world [5, 6] . Monitoring of the antiviral resistance of A(H1N1) viruses is important because of the widespread resistance of seasonal A(H1N1) viruses to oseltamivir beginning in the 2007-2008 season [7, 8] . Drug-resistant pandemic A(H1N1) viruses that could acquire the ability to be transmitted efficiently among humans pose a considerable public health concern.
In Japan, the first pandemic influenza case was reported in May 2009 [9] . In mid-June 2009, the pandemic influenza A(H1N1) virus had spread throughout Japan and by mid-July, all 47 prefectures were affected [10] . Phylogenetic analysis of these pandemic stage viruses revealed that the A(H1N1)pdm09 virus had evolved since its first appearance in the country [11] . Sequence analysis of viruses from the very early phase (May 2009) and from the peak phase (October 2009 to January 2010) of the pandemic identified distinct mutations in the HA and NA that clearly differentiate viruses from these two time periods [12] .
In this study, we described the circulation patterns and genetic characteristics of viruses that circulated during the pandemic and post-pandemic periods. We focused on the comparison of pandemic influenza A(H1N1) viruses collected in Japan in the 2009-2010 and 2010-2011 seasons. In addition, we performed genetic analysis on A(H3N2) and influenza B viruses that cocirculated with the A(H1N1)pdm09 viruses in the 2010-2011 season.
Results

Clinical Background of Patients
Seven hundred thirty three (733) patients with influenza-like illness who visited outpatient clinics in six prefectures in Japan (Fukushima, Gunma, Niigata, Kyoto, Hyogo and Nagasaki) between July 2009 and February 2010, and 1,278 patients in seven prefectures (Hokkaido, Niigata, Gunma, Kyoto, Hyogo, Osaka and Nagasaki) from December 2010 to March 2011 participated in our study. Among these patients, 4 from the 2009-2010 period and 14 from the 2010-2011 period were hospitalized after the initial assessment of the severity of infection at the outpatient clinic (data not shown). All of the hospitalized patients from the two periods fully recovered. There were no patients with lethal infection.
Laboratory Surveillance of Influenza Viruses
Of the 733 respiratory specimens that were collected from patients with influenza-like illness in the 2009-2010 season, 601 A(H1N1)pdm09 viruses (85.4%) were isolated, as confirmed by the real-time PCR assays (Table 1) . A part of the samples were verified by hemagglutination inhibition (HI) test. A(H1N1)pdm09 influenza virus activity peaked in November 2009 (week 47) ( Figure 1 ) which was 2-3 months earlier than in previous years. No other type or subtype of influenza viruses was detected during this period. The pandemic A(H1N1) 2009 virus had completely replaced the seasonal A(H1N1) virus in the areas studied within the surveillance period.
Of the 1,278 respiratory specimens that were collected in the 2010-2011 season 972 (76.1%) viruses were isolated. There was cocirculation of different types and subtypes of influenza viruses in this season and were distributed as follows: 414 A(H1N1)pdm09 (42.6%), 525 A(H3N2) (54.0%) and 33 influenza B (3.4%) viruses (Table 1) . There were no influenza B viruses detected in Hokkaido, Gunma and Osaka prefectures. Pandemic A(H1N1) 2009 virus activity peaked in January (weeks 3 and 4) while A(H3N2) virus activity peaked in February (week 6) ( Figure 1 ).
There was variability in the influenza virus subtype predominance in each prefecture. A(H3N2) viruses were predominant in Hokkaido, Niigata and Gunma prefectures in the northern area of Japan, as well as in Nagasaki in the south. A(H1N1)pdm09 viruses were predominant in prefectures in the Kansai area of western Japan: Kyoto, Hyogo and Osaka (Table 1, Figure 2 ).
Among influenza B viruses, 31 out of 33 (93.9%) isolates belong to the Victoria lineage and 2 out of 33 (6.1%) isolates belong to the Yamagata lineage, according to cycling probe real time PCR results (Table 1) .
Detection of H275Y Mutation in the NA
All of the 601 A(H1N1)pdm09 viruses from the 2009-2010 period showed possession of H275 (wild-type) in the neuraminidase (NA) by screening with cycling probe real-time PCR and/ or by genetic sequencing. These results suggested possible susceptibility to oseltamivir among the collected specimens.
In the 2010-2011 season, 2 out of 414 (0.5%) isolates harbor the H275Y mutation in NA as shown by cycling probe assay and sequencing. These viruses were from primary respiratory specimens of patients with no prior treatment of oseltamivir.
Detection of S31N Mutation in the M2
All of the 1,015 A(H1N1)pdm09 isolates in the two seasons were tested for the presence of M2-S31N substitution that confers resistance to amantadine using the cycling probe real time PCR method. All but two viruses possessed the M2-S31N change: A/ Nagasaki/09N079/2009 and A/Kyoto/09K084/2009 had serine (AGT) at position 31 (as confirmed by sequencing of the transmembrane domain of the M2 gene) suggesting susceptibility to amantadine. All A(H1N1)pdm09 viruses from the 2010-2011 season harbor the S31N mutation in M2 (Table 1) .
Among the A(H3N2) isolates, 520/525 (99.0%) had the M2-S31N substitution according to cycling probe real time PCR results (Table 1) , suggesting resistance to amantadine. Among these mutations, 5 are located in antigenic sites Ca (G170E, S203T, R205K and D222E) and Cb (L70F) [14] ( Figure 3A , Figure 4A) . A(H1N1)pdm09 viruses from the 2010-2011 season exhibited additional amino acid changes in the HA from the previous season's strains. Amino acid substitutions S185T and A197T were observed in fifty-three (53) isolates analyzed. Amino acid mutations A134T, A141S, S183P and I295V were detected in two (2) isolates. When compared with the vaccine strain, 4-14 amino acid mutations were identified. Several of these mutations are localized in antigenic sites Ca (A141S, G140E, I166V and E235K), Sa (K153T, K160M, K163N and K163T) and Sb (S185T and A186T) ( Figure 3A , Figure 4A ). HI test with selected strains showed similar antigenicity with the vaccine strain despite several amino acid changes at putative antigenic sites (Table S1 ).
Phylogenetic Analysis
An amino acid change from aspartic acid (D) to glutamic acid (E) was observed at residue 222 in the HA in 6 isolates from the 2009-2010 season. However, this amino acid substitution was not found in 2010-2011 isolates. Glycine (G) or asparagine (N) mutation at amino acid residue 222, which were previously reported to be associated with severe illness [15, 16] , were not observed among the isolates from both seasons.
The NA phylogenetic tree was generally congruent with that of the HA ( Figure 3B (Table S2 ).The Vic208 clade was characterized by the amino acid change T212A located in antigenic site C. Interestingly, geographical and temporal clustering was observed (Table S3) .
The NA phylogeny showed that all viruses belonged to the Yamagata-lineage but the clustering into two distinct groups was similar to that of the HA ( Figure 7B ). Within the Brisbane60 clade, 13 amino acid changes were observed; of which, 2 are found in antigenic sites F' (N329D) and G (N340D) ( Figure 5C ). Within the Bangladesh3333 clade, 8 amino acid substitutions were identified wherein 1 amino acid change is located in the antigenic site G' (D340N) ( Figure 5C , Figure 7B ).
Discussion
The pandemic influenza A(H1N1) virus first appeared in Japan in May 2009 and reached the pandemic stage in June 2009 [9] . In the course of the surveillance study we conducted during the The decrease in the number of clinical cases may be attributed to an increase in antibody levels against the A(H1N1)pdm09 virus in the community [22, 23] . This is supported by the results of the sero-surveillance studies conducted by the Infectious Disease Surveillance Center in 2009 and in 2010 that showed a substantial increase in the antibody levels of those surveyed in 2010, reaching a high prevalence rate of over 50% among school-aged children, when compared with the antibody levels in 2009 (prevalence rate Influenza A(H3N2) was the predominant influenza type-A virus that caused illness in the 2010-2011 season in our study. Strain predominance varied among prefectures but geographic clustering was evident. Prefectures in northern Japan had 4 to 7 times more A(H3N2) viruses detected than A(H1N1)pdm09 viruses. Prefectures in the Kansai area (Kyoto, Hyogo and Osaka) had about 2 to 4 times more A(H1N1)pdm09 viruses detected than A(H3N2) viruses. Influenza virus peak activity also varied among the type-A viruses. The A(H1N1)pdm09 virus activity peaked in late January whereas A(H3N2) virus activity peaked in mid-February. We could not assess the peak of influenza B due to the termination of the study in early March. According to the National Influenza Surveillance in Japan, more influenza B viruses than influenza A viruses were detected after week 12 until week 20 (http://idsc.nih. go.jp/iasr/influ-e.html) in Japan.
Characteristics of A(H1N1)pdm09 Viruses
In the first year of pandemic (2009-2010), we did not detect any oseltamivir-resistant A(H1N1)pdm09 viruses. In the following season, we detected two (2) A(H1N1)pdm09 viruses (0.5% prevalence) that possessed the H275Y substitution in the NA. These two isolates came from patients who had not received oseltamivir treatment, live in different areas and were infected at different times. There was no epidemiological link established between the two cases. These naturally-occurring oseltamivirresistant A(H1N1)pdm09 viruses in untreated patients were previously reported in Hong Kong and Vietnam [24, 25] . The reported oseltamivir-resistant A(H1N1)pdm09 viruses in Japan in the 2009-2010 season mostly came from patients who received oseltamivir as treatment and as prophylaxis, which suggested sporadic emergence from oseltamivir-sensitive A(H1N1)pdm09 viruses due to selective drug pressure [26] . The two oseltamivirresistant A(H1N1)pdm09 strains in this study showed a clustering in the NA phylogeny due to the H275Y amino acid substitution, but not in the HA phylogeny. In contrast, the oseltamivir-resistant seasonal A(H1N1) viruses isolated in the 2008-2009 season showed a clustering in both the HA and NA phylogenies with signature amino acid changes other than the H275Y mutation in Japan [8] . The low prevalence of oseltamivir-resistant A(H1N1)pdm09 viruses in this study suggests limited community transmission.
The A(H1N1)pdm09 virus contains the M gene of the Eurasian swine lineage (originally derived from an avian influenza virus) and has the genetic marker (S31N in M2) for resistance to amantadine [27] . In this study, two A(H1N1)pdm09 viruses from the 2009-2010 period have serine (S) at residue 31 of the M2. These viruses were susceptible to amantadine based on the phenotypic assay TCID 50 (results not shown). DNA sequencing of the M gene of these two viruses showed that the sensitivity was due to a spontaneous mutation in the M2 segment and was not due to a reassortment with an amantadine-sensitive gene segment. From a CDC report [28] , it can be inferred that 0.2% (4/1899) of A(H1N1)pdm09 viruses tested were also sensitive to amantadine which suggests that these rare amantadine-sensitive viruses were in circulation in the 2009-2010 season. However, in the following season amantadine-sensitive A(H1N1)pdm09 viruses were not detected in our study.
Based on the HA and NA sequence data of viruses collected within the pandemic period from July 2009 to February 2010, The amino acid change S143G, which is found in 29/55 (52.7%) of viruses analyzed, is located next to the antigenic site Ca. In a previous report [29] , two (2) viruses with the S143G substitution were observed to have reduced antigenicity against the A/ California/07/2009 vaccine virus in the HI test. However, selected A(H1N1)pdm09 viruses with the S143G mutation from our study did not show a reduction in the HI titer when compared with the vaccine strain. These mutations in the HA did not contribute to a change in antigenicity of the A(H1N1)pdm09 viruses in our study.
The amino acid substitutions HA-D222G/N in A(H1N1)pdm09 viruses were previously associated with severe infection [15, 16] . These mutations were not detected among the 81 isolates analyzed from the 2009-2010 season. Instead, a D222E substitution was found in 6 isolates representing 1.0% of viruses from the 2009-2010 period. This mutation was observed to be not associated with severe infection [16] . In the 2010-2011 season, the D222E mutation did not persist and all viruses had the wild-type genotype. The D222G/N mutations were not found in viruses in this season.
A new amino acid mutation in the NA of A(H1N1)pdm09 viruses associated with reduced susceptibility to neuraminidase inhibitors were recently reported. A mild reduction in oseltamivir and zanamivir susceptibility was observed in viruses from Oceania and Southeast Asia with the S247N (serine to asparagine) mutation [30] . We have not found this mutation in the viruses we analyzed. [35] . In addition, only a small percentage of influenza A viruses tested was resistant to oseltamivir but almost all were resistant to amantadine.
Characteristics of A(H3N2) Viruses
It remains to be seen whether the pandemic A(H1N1) 2009 virus will follow the path of other pandemic viruses such as that of the Asian influenza A(H2N2) virus which survived shortly in the human population and disappeared 11 years after its emergence [36] or that of the Hong Kong influenza A(H3N2) virus which 43 years later still remains an important cause of influenza illness in humans [36] .
Materials and Methods
Study Design
Eligible patients to this study were those who visited outpatient clinics presented with influenza-like illness symptoms (fever of $37.5uC, cough and/or sore throat) and had not been treated with amantadine, oseltamivir or zanamivir within the previous four weeks. The study period was between July 30, 2009 and March 22, 2011. The Niigata University Division of International Health (Public Health) supplied viral transport media to clinicians participating in the Japanese Influenza Collaborative Study Group (18 clinics in eight Prefectures in Japan: Hokkaido, Fukushima, Gunma, Niigata, Kyoto, Hyogo, Osaka and Nagasaki Prefectures). Clinicians performed an influenza rapid diagnostic test, mainly by using the Quick-Ex Flu kit (Denka Seiken, Co. Ltd., Tokyo, Japan), on the first respiratory specimen, and collected a second respiratory specimen regardless of the rapid test results. The samples were stored in viral transport media for #72 hours at 4uC before shipment to our laboratory. Informed written consent was obtained from the patient or the patient's guardian prior to specimen collection. The study was approved by the medical faculty ethics committee of the Niigata University Graduate School of Medical and Dental Sciences.
Virus Isolation and Characterization
About 100 ml of nasopharyngeal sample was inoculated onto Madin-Darby canine kidney (MDCK) cells. MDCK cell lines were kindly provided by Dr. Hidekazu Nishimura of Virus Center, Sendai National Medical Center, Miyagi Prefecture, Japan and were maintained as previously described [37] . Cultures were monitored for cytopathic effect (CPE) for 3-7 days. All isolates were typed and subtyped by cycling probe real-time PCR assays. Selected influenza isolates underwent a hemagglutination inhibition (HI) assay using guinea pig red blood cells (Toyo Bio, Tokyo, Japan) and commercially available influenza vaccine strain antisera: 
RNA Extraction and cDNA Synthesis
Total RNA was extracted from 100 ml of clinical specimens and from 100 mL of viral culture using Extragen II kit (Kainos, Tokyo, Japan) following manufacturer's instructions. First-strand cDNA synthesis was performed using influenza A and B universal primers [37, 38] .
Real-time PCR Genotyping of Drug-resistant Strains
Cycling probe real-time PCR screening for mutations in M2 and NA genes that confer resistance to amantadine and oseltamivir, respectively, was performed on all 1,540 influenza A virus isolates (2009-2010 and 2010-2011) using fluorescentlabeled chimeric RNA-DNA probes and RNaseH (TaKaRa Bio Inc., Ohtsu, Japan). This assay utilizes a single nucleotide polymorphism (SNP) which can simultaneously detect amantadine-sensitive (S31) and amantadine-resistant (S31N) viruses as previously described [39] . Similarly, another single nucleotide polymorphism which can distinguish between oseltamivir-sensitive (H275) and oseltamivir-resistant (H275Y) viruses was used as previously described [40] . SNP typing was performed using Thermal Cycler Dice Real Time PCR System TP800 (TaKaRa Bio Inc., Ohtsu, Japan).
Cycling Probe Real-time PCR Method for Influenza B Samples that were negative for the screening methods for A(H1N1)pdm09 and A(H3N2) were tested using a cycling probe real-time PCR method that can distinguish Victoria-lineage and Yamagata-lineage influenza B viruses according to the HA gene sequence.
For the influenza B cycling probe real time PCR reaction, a commercially available cycling probe real time PCR kit, TaKaRa CycleavePCRHCore Kit (TaKaRa Bio Inc., Ohtsu, Japan) was used. The PCR reaction was prepared according to the manufacturer's instructions and was supplemented with 5 pmol of each primer (a forward primer, a Victoria lineage-specific reverse primer and a Yamagata lineage-specific reverse primer), 2.5 pmol of the carboxyfluorescein (FAM)-labeled probe (Victoria HA gene-specific), 2.5 pmol of the carboxy-X-rhodamine (ROX)-labeled probe (Yamagata HA gene-specific), and 1 mL of viral cDNA in a 25 ml reaction volume. PCR amplification and fluorescence detection were performed on Thermal Cycler Dice Real Time PCR System TP800 (TaKaRa Bio Inc., Ohtsu, Japan). Cycling conditions were as follows: denaturation at 95uC for 10 seconds followed by 40 cycles of denaturation at 95uC for 5 seconds, primer annealing at 57uC for 10 seconds, and extension and subsequent detection of fluorescence at 72uC for 15 seconds (primers and probes information are available on request).
DNA Sequencing and Phylogenetic Analysis
The HA and NA genes of 136 A(H1N1)pdm09, 71 A(H3N2) and 29 influenza B viruses, as well as the M gene of 6 A(H1N1)pdm09 viruses from the 2009-2010 season, were amplified using gene-specific primers. PCR products were purified using MSBP Spin PCRapace kit (Invitek GmbH, Berlin, Germany) and directly sequenced. Sequencing reactions were carried out using BigDye Terminator v3.1 cycle sequencing kit (Applied Biosystems, Carlsbad, USA) and sequencing products were run on an ABI Prism 3100 Genetic Analyzer. Sequences were assembled using Lasergene SeqMan Pro package version 7.2.1 (DNASTAR, Madison, USA) and assembled sequences were edited using BioEdit software (http://www.mbio.ncsu.edu/ BioEdit/). Phylogenetic analysis was performed using MEGA 4.0 software [41] (Molecular Evolutionary Genetics Analysis). Bestfitting trees for the HA and NA genes were constructed by the Neighbor-Joining method [42] with the maximum composite likelihood model [43] and bootstrap analysis of 1,000 replicates. Antigenic Site Mapping of HA and NA HA and NA amino acid sequences of influenza virus isolates in Japan were compared with the vaccine strains. Identified amino acid substitutions were mapped to reported HA antigenic sites [14, 18, 20] and NA antigenic sites [17, 19] . Crystal structures of HA (PDB entry 3LZG for H1, 1MQL for H3, and 2RFT for type B) and NA (PDB entry 3NSS for N1, 1IVG for N2, and 1INF for type B) were downloaded from Protein Data Bank (RCSB PDB, http://www.pdb.org) [44] . Molecular models were analyzed using the PyMol software v1.3 (http://www.pymol.org). 
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